Glycerol Phenylbutyrate in Patients With Cirrhosis and Episodic Hepatic Encephalopathy: A Pilot Study of Safety and Effect on Venous Ammonia Concentration
- 16 March 2013
- journal article
- research article
- Published by Wiley in Clinical Pharmacology in Drug Development
- Vol. 2 (3), 278-284
- https://doi.org/10.1002/cpdd.18
Abstract
Glycerol tri-(4-phenylbutyrate) (glycerol phenylbutyrate, GPB, HPN-100) mediates waste nitrogen excretion through conjugation with glutamine to form phenylacetylglutamine which is excreted in urine. This pilot study was performed to assess tolerability and effect on venous ammonia concentration in patients with cirrhosis and hepatic encephalopathy (HE). Patients underwent one week of 6 mL (6.6 g) twice daily (BID). GPB dosing followed by 3 weeks of 9 mL (9.9 g) BID dosing and underwent repeated blood sampling for ammonia concentration and pharmacokinetics. Fifteen patients were enrolled. Ammonia concentrations were lowest after overnight fast and increased post-prandially. Fasting ammonia concentrations were lower on GPB compared to baseline, with a decrease on the eighth day of 6 mL BID dosing to 45.4 (27.9) µmol/L (ULN ∼48 µmol/L) (P < .05). Nine milliliters BID yielded similar lowering but was associated with more adverse events and higher phenylacetate (PAA) plasma concentrations (PAA Cmax of 144 [125] vs. 292 [224] µg/mL on 6 and 9 mL, respectively). GPB dosed at 6 mL BID lowered fasting ammonia levels in cirrhotic patients with HE as compared with baseline, was better tolerated than 9 mL BID, and is appropriate for further evaluation in patients with cirrhosis and episodic HE.Keywords
This publication has 12 references indexed in Scilit:
- Ammonia control and neurocognitive outcome among urea cycle disorder patients treated with glycerol phenylbutyrateHepatology, 2012
- Ammonia control in children with urea cycle disorders (UCDs); Phase 2 comparison of sodium phenylbutyrate and glycerol phenylbutyrateMolecular Genetics and Metabolism, 2011
- Phase 2 comparison of a novel ammonia scavenging agent with sodium phenylbutyrate in patients with urea cycle disorders: Safety, pharmacokinetics and ammonia controlMolecular Genetics and Metabolism, 2010
- 195 RIFAXIMIN DECREASES VENOUS AMMONIA CONCENTRATIONS AND TIME-WEIGHTED AVERAGE AMMONIA CONCENTRATIONS CORRELATE WITH OVERT HEPATIC ENCEPHALOPATHY (HE) AS ASSESSED BY CONN SCORE IN A 6-MONTH STUDYJournal of Hepatology, 2010
- Rifaximin Treatment in Hepatic EncephalopathyThe New England Journal of Medicine, 2010
- Pharmacology and safety of glycerol phenylbutyrate in healthy adults and adults with cirrhosisHepatology, 2010
- An Algorithm for the Management of Hepatic EncephalopathySeminars in Liver Disease, 2007
- Emerging Therapies for the Management of Hepatic EncephalopathySeminars in Liver Disease, 2007
- Treatment Options for Hepatic Encephalopathy: A ReviewSeminars in Liver Disease, 2007
- Maximal Rates of Excretion and Synthesis of Urea in Normal and Cirrhotic SubjectsJCI Insight, 1973